OncoMatch/Clinical Trials/NCT06911710
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Is NCT06911710 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） for lymphoma, b-cell, aggressive non-hodgkin (b-nhl).
Treatment: CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） — This study is an open, single-arm, prospective, Phase I/II clinical study using "3+3" dose escalation and dose expansion to investigate the safety, maximum tolerated dose, in vivo pharmacokinetic profile, and preliminary efficacy of CAR-T cell injections for the treatment of relapsed/refractory malignant hematological neoplasms in subjects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Multiple Myeloma
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 overexpression
Diagnosis of CD19+ ... confirmed by pathology and histology
Required: CD20 overexpression
Diagnosis of ... CD20+ ... confirmed by pathology and histology
Required: CD22 overexpression
Diagnosis of ... CD22+ ... confirmed by pathology and histology
Required: TNFSF13B overexpression
Diagnosis of ... BAFF+ ... confirmed by pathology and histology
Required: CD7 overexpression
Diagnosis of CD7+ refractory/relapsed T-lymphocyte lymphoma confirmed by pathology and histology
Required: BCMA overexpression
Positive expression of BCMA ... in myeloma cells by flow or immunohistochemistry
Required: GPRC5D overexpression
Positive expression of ... GPRC5D in myeloma cells by flow or immunohistochemistry
Required: CD47 overexpression
Positive tumor cell antigen test results (CD7 and/or CD19 and/or CD47) confirmed by immunohistochemistry or flow cytometry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 monoclonal antibody
subjects must have received adequate prior therapy, including at least: Anti-CD20 monoclonal antibody
Must have received: anthracycline-containing combination chemotherapy
subjects must have received adequate prior therapy, including at least: ... Anthracycline-containing combination chemotherapy
Must have received: proteasome inhibitor
Patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) or are resistant to proteasome inhibitors and/or immunomodulatory agents
Must have received: immunomodulatory drug
Patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy (including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs)) or are resistant to proteasome inhibitors and/or immunomodulatory agents
Must have received: stem cell transplant
disease relapse after having undergone stem cell transplantation to achieve complete remission
Lab requirements
Blood counts
hgb ≥ 60g/l (transfusion is allowed)
Kidney function
creatinine ≤1.5×uln
Liver function
total bilirubin ≤ 1.5 × uln; alt and ast ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction ≥50%; blood oxygen saturation >90%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06911710 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received anti-CD20 monoclonal antibody and anthracycline-containing combination chemotherapy.
Does this trial require CD19?
Yes, CD19 overexpression is a required biomarker for enrollment.
Does this trial require CD20?
Yes, CD20 overexpression is a required biomarker for enrollment.
Does this trial require CD22?
Yes, CD22 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify